2024
Comparative effectiveness of different corticosteroid regimens in severe alcohol-associated hepatitis
Islam A, Díaz L, Idalsoaga F, Guizzetti L, Mortuza R, Dunn W, Singal A, Simonetto D, Ramirez-Cadiz C, Zhang W, Qian S, Cabezas J, Sarin S, Maiwall R, Jalal P, La Tijera F, Skladany L, Bystrianska N, Rincon D, Chacko K, Cots M, Garcia-Tsao G, Abraldes J, Kamath P, Arrese M, Shah V, Bataller R, Arab J. Comparative effectiveness of different corticosteroid regimens in severe alcohol-associated hepatitis. Hepatology Communications 2024, 8: e0573. PMID: 39445912, PMCID: PMC11512629, DOI: 10.1097/hc9.0000000000000573.Peer-Reviewed Original ResearchViral antibody response predicts morbidity and mortality in alcohol-associated hepatitis.
Hsu C, Wang L, Maestri E, Jacob A, Do W, Mayo S, Bosques-Padilla F, Verna E, Abraldes J, Brown R, Vargas V, Altamirano J, Caballería J, Shawcross D, Louvet A, Lucey M, Mathurin P, Garcia-Tsao G, Stärkel P, Bataller R, Investigators A, Wang X, Schnabl B. Viral antibody response predicts morbidity and mortality in alcohol-associated hepatitis. Hepatology 2024 PMID: 39325984, DOI: 10.1097/hep.0000000000001046.Peer-Reviewed Original ResearchAlcohol-associated hepatitisAlcohol use disorderHigher Child-Pugh scoreSerological profileAntibody responseAssociated with very high mortalityUse disorderDecompensation of liver diseaseChild-Pugh scoreActive alcohol useNinety-day mortalityAssociated with decompensationMulticenter observational studyViral antibody responseMonths of diagnosisAntibody repertoireSera of patientsMultiorgan dysfunctionPoor prognosisNinety-daySerological biomarkersHealthy controlsPatient seraLiver diseaseAntibody targetingRelationship between updated MELD and prognosis in alcohol-associated hepatitis: Opportunities for more efficient trial design
Al-Karaghouli M, Ventura-Cots M, Wong Y, Genesca J, Bosques F, Brown R, Mathurin P, Louvet A, Shawcross D, Vargas V, Verna E, Schnabl B, Caballeria J, Shah V, Kamath P, Lucey M, Garcia-Tsao G, Bataller R, Abraldes J. Relationship between updated MELD and prognosis in alcohol-associated hepatitis: Opportunities for more efficient trial design. Hepatology Communications 2024, 8: e0495. PMID: 39082963, DOI: 10.1097/hc9.0000000000000495.Peer-Reviewed Original ResearchConceptsAlcohol-associated hepatitisTrial designRandomized controlled trialsShort-term mortalityInclusion criteriaPredictive valuePrognostic valueControlled trialsShort-term benefitsEfficient trial designTrial outcomesAssociated with significant mortalityCourse of AHCohort of patientsTreatment decisionsSample sizeOrdinal outcomesMortalityOrdinal scaleMELD valuesLandmark analysisTransplant allocationTrialsOutcomesTransplantationFaecal proteomics links neutrophil degranulation with mortality in patients with alcohol-associated hepatitis
Kreimeyer H, Gonzalez C, Fondevila M, Hsu C, Hartmann P, Zhang X, Stärkel P, Bosques-Padilla F, Verna E, Abraldes J, Brown R, Vargas V, Altamirano J, Caballería J, Shawcross D, Louvet A, Lucey M, Mathurin P, Garcia-Tsao G, Bataller R, Investigators A, Gonzalez D, Schnabl B. Faecal proteomics links neutrophil degranulation with mortality in patients with alcohol-associated hepatitis. Gut 2024, gutjnl-2024-332730. PMID: 39033024, DOI: 10.1136/gutjnl-2024-332730.Peer-Reviewed Original ResearchAlcohol-associated hepatitisShort-term survivalMulticentre cohortSeverity of ALDAlcohol-associated liver diseaseIndependent validation cohortInduce gut dysbiosisNon-invasive markerAlcohol-use disordersNeutrophil degranulationPrediction of short-term survivalPrognostic effectHepatic neutrophilsValidation cohortBacterial translocationNeutrophil granulesMPO levelsLiver diseaseFecal biomarkersTandem mass tagPatientsGut dysbiosisLiver damageDisease severityNeutrophilsEASL International Recognition Award Recipient 2024: Prof. Norah Terrault
Buti M, Campos-Varela I, Garcia-Tsao G. EASL International Recognition Award Recipient 2024: Prof. Norah Terrault. Journal Of Hepatology 2024, 81: 9-10. DOI: 10.1016/j.jhep.2024.04.012.Peer-Reviewed Original ResearchManagement of acute variceal bleeding
Mohanty A, Garcia-Tsao G. Management of acute variceal bleeding. Clinical Liver Disease 2024, 23: e0176. PMID: 38952694, PMCID: PMC11216663, DOI: 10.1097/cld.0000000000000176.Peer-Reviewed Original ResearchFRI-086 Untargeted serum metabolomic profiles remain stable over time in large multi-center cohort of >700 outpatients with cirrhosis
Bajaj J, Tandon P, Lai J, O'Leary J, Garcia-Tsao G, Vargas H, Biggins S, Wong F, Kamath P, Lugon N, Limon-Miro A, Shaw J, Bush B, Reddy K. FRI-086 Untargeted serum metabolomic profiles remain stable over time in large multi-center cohort of >700 outpatients with cirrhosis. Journal Of Hepatology 2024, 80: s218. DOI: 10.1016/s0168-8278(24)00868-7.Peer-Reviewed Original ResearchFRI-046 Alfapump implantation significantly improved quality of life and showed similar safety outcomes compared to a contemporaneously enrolled refractory ascites cohort
Bajaj J, Kamath P, Reddy K, Tandon P, Lai J, O'Leary J, Klarenbeek G, Capel J, Biggins S, Vargas H, Garcia-Tsao G, Thacker L, Wong F. FRI-046 Alfapump implantation significantly improved quality of life and showed similar safety outcomes compared to a contemporaneously enrolled refractory ascites cohort. Journal Of Hepatology 2024, 80: s206. DOI: 10.1016/s0168-8278(24)00843-2.Peer-Reviewed Original ResearchSu1979 GUTGPT: NOVEL LARGE LANGUAGE MODEL PIPELINE OUTPERFORMS OTHER LARGE LANGUAGE MODELS IN ACCURACY AND SIMILARITY TO INTERNATIONAL EXPERTS FOR GUIDELINE RECOMMENDED MANAGEMENT OF PATIENTS WITH UPPER GASTROINTESTINAL BLEEDING
Giuffrè M, You K, Chung S, Kresevic S, Chan C, Saarinen T, Nakamura S, Laine L, Sung J, Garcia-Tsao G, Gralnek I, Barkun A, Sekhon J, Shung D. Su1979 GUTGPT: NOVEL LARGE LANGUAGE MODEL PIPELINE OUTPERFORMS OTHER LARGE LANGUAGE MODELS IN ACCURACY AND SIMILARITY TO INTERNATIONAL EXPERTS FOR GUIDELINE RECOMMENDED MANAGEMENT OF PATIENTS WITH UPPER GASTROINTESTINAL BLEEDING. Gastroenterology 2024, 166: s-889-s-890. DOI: 10.1016/s0016-5085(24)02528-9.Peer-Reviewed Original ResearchSa1592 STROOP PERFORMANCE AND OPIOID USE PREDICT 3-MONTH HOSPITALIZATION IN THE MULTI-CENTER PROSPECTIVE OUTPATIENT NACSELD-3 COHORT
Bajaj J, Tandon P, Lai J, O'Leary J, Wong F, Garcia-Tsao G, Vargas H, Biggins S, Kamath P, Thacker L, Reddy R. Sa1592 STROOP PERFORMANCE AND OPIOID USE PREDICT 3-MONTH HOSPITALIZATION IN THE MULTI-CENTER PROSPECTIVE OUTPATIENT NACSELD-3 COHORT. Gastroenterology 2024, 166: s-1588-s-1589. DOI: 10.1016/s0016-5085(24)04108-8.Peer-Reviewed Original ResearchReply: On the use of nonselective beta blockers in cirrhosis
Garcia-Tsao G, Kaplan D. Reply: On the use of nonselective beta blockers in cirrhosis. Hepatology 2024, 80: e35-e35. PMID: 38626347, DOI: 10.1097/hep.0000000000000889.Peer-Reviewed Original ResearchAn artificial intelligence-generated model predicts 90-day survival in alcohol-associated hepatitis: A global cohort study
Dunn W, Li Y, Singal A, Simonetto D, Díaz L, Idalsoaga F, Ayares G, Arnold J, Ayala-Valverde M, Perez D, Gomez J, Escarate R, Fuentes-López E, Ramirez-Cadiz C, Morales-Arraez D, Zhang W, Qian S, Ahn J, Buryska S, Mehta H, Dunn N, Waleed M, Stefanescu H, Bumbu A, Horhat A, Attar B, Agrawal R, Cabezas J, Echavaría V, Cuyàs B, Poca M, Soriano G, Sarin S, Maiwall R, Jalal P, Higuera-de-la-Tijera F, Kulkarni A, Rao P, Guerra-Salazar P, Skladaný L, Kubánek N, Prado V, Clemente-Sanchez A, Rincon D, Haider T, Chacko K, Romero G, Pollarsky F, Restrepo J, Toro L, Yaquich P, Mendizabal M, Garrido M, Marciano S, Dirchwolf M, Vargas V, Jiménez C, Hudson D, García-Tsao G, Ortiz G, Abraldes J, Kamath P, Arrese M, Shah V, Bataller R, Arab J. An artificial intelligence-generated model predicts 90-day survival in alcohol-associated hepatitis: A global cohort study. Hepatology 2024, 80: 1196-1211. PMID: 38607809, DOI: 10.1097/hep.0000000000000883.Peer-Reviewed Original ResearchAlcohol-associated hepatitisValidation cohortArtificial intelligenceModified Glasgow scoreMaddrey's discriminant functionMortality rateGlobal cohort studyShort-term mortalityPost-test probabilityApproximate mortality ratesSteroid therapyGlasgow scoreAH patientsSteroid useTransplant indicationRetrospective studyDerivation cohortLaboratory valuesCohort studyClinical trialsGlobal cohortPrognostic modelScoring systemAI algorithmsCohortReply: Endoscopy for potential variceal bleeding within 12 hours—Not so fast!
Garcia-Tsao G, Kaplan D. Reply: Endoscopy for potential variceal bleeding within 12 hours—Not so fast! Hepatology 2024, 80: e36-e36. PMID: 38607742, DOI: 10.1097/hep.0000000000000881.Peer-Reviewed Original ResearchAcute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting
Nadim M, Kellum J, Forni L, Francoz C, Asrani S, Ostermann M, Allegretti A, Neyra J, Olson J, Piano S, VanWagner L, Verna E, Akcan-Arikan A, Angeli P, Belcher J, Biggins S, Deep A, Garcia-Tsao G, Genyk Y, Gines P, Kamath P, Kane-Gill S, Kaushik M, Lumlertgul N, Macedo E, Maiwall R, Marciano S, Pichler R, Ronco C, Tandon P, Velez J, Mehta R, Durand F. Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting. Journal Of Hepatology 2024, 81: 163-183. PMID: 38527522, PMCID: PMC11193657, DOI: 10.1016/j.jhep.2024.03.031.Peer-Reviewed Original ResearchAcute Disease Quality InitiativeInternational Club of AscitesAcute kidney injuryHRS-AKIQuality InitiativeHepatorenal syndromePost-discharge follow-upKidney injuryMultidisciplinary consensus meetingRisk of progression to chronic kidney diseaseProgression to chronic kidney diseasePhenotypes of acute kidney injuryFollow-up of patientsBridge to liver transplantationIncreased in-hospital morbidityIn-hospital morbidityPost-discharge follow-up of patientsChronic kidney diseaseMortality riskConsensus meetingInternational ClubCurative optionSplanchnic vasoconstrictorsAdvanced cirrhosisLiver transplantationSerum aryl hydrocarbon receptor activity is associated with survival in patients with alcohol-associated hepatitis
Yamazaki T, Kouno T, Hsu C, Hartmann P, Mayo S, Zhang X, Stärkel P, Bosques-Padilla F, Verna E, Abraldes J, Brown R, Vargas V, Altamirano J, Caballería J, Shawcross D, Louvet A, Lucey M, Mathurin P, Garcia-Tsao G, Bataller R, Investigators A, Schnabl B. Serum aryl hydrocarbon receptor activity is associated with survival in patients with alcohol-associated hepatitis. Hepatology 2024, 80: 403-417. PMID: 38377466, PMCID: PMC11268475, DOI: 10.1097/hep.0000000000000777.Peer-Reviewed Original ResearchAlcohol-associated hepatitisAlcohol use disorderSevere AHAH patientsAhR activationMicrobiota-derived tryptophan metabolitesSurvival rateAssociated with high mortalityCumulative survival rateAssociated with survivalAryl hydrocarbon receptor activationMulticenter cohortFecal metabolomePrognostic markerTryptophan metabolitesReceptor activationAryl hydrocarbon receptorPatientsUse disorderAH cohortSerumHigher mortalityAhRHepatitisCohortP-19 CHARACTERIZATION, PROGNOSTIC FACTORS, AND SURVIVAL IN MODERATE ALCOHOL-ASSOCIATED HEPATITIS: A MULTICENTER STUDY
Idalsoaga F, Díaz L, Corsi O, Ayares G, Arnold J, Dunn W, Li Y, Singal A, Simonetto D, Ayala-Valverde M, Ramirez C, Morales-Arraez D, Zhang W, Qian S, Ahn J, Buryska S, Mehta H, Waleed M, Stefanescu H, Horhat A, Bumbu A, Attar B, Agrawal R, Cabezas J, Cuyàs B, Poca M, Pastor G, Sarin S, Maiwall R, Jalal P, La Tijera M, Kulkarni A, Rao N, Salazar P, Skladaný L, Bystrianska N, Prado V, Clemente-Sanchez A, Rincón D, Haider T, Chacko K, Romero G, Pollarsky F, Restrepo J, Toro L, Yaquich P, Mendizabal M, Garrido M, Marciano S, Dirchwolf M, Vargas V, Jimenez C, García-Tsao G, Ortiz G, Abraldes J, Kamath P, Shah V, Bataller R, Arab J. P-19 CHARACTERIZATION, PROGNOSTIC FACTORS, AND SURVIVAL IN MODERATE ALCOHOL-ASSOCIATED HEPATITIS: A MULTICENTER STUDY. Annals Of Hepatology 2024, 29: 101206. DOI: 10.1016/j.aohep.2023.101206.Peer-Reviewed Original ResearchRenal replacement therapyVariables associated with mortalityModerate AHAlcohol-associated hepatitisPrognostic factorsLiver transplantationMaddrey's discriminant functionAssociated with high mortalityMultiple organ failureRetrospective cohort studyMultivariate-adjusted modelsShort-term mortalityAssociated with mortalityCompeting-risks modelMedian ageCause of deathReplacement therapyMulticenter studyMELD scoreOrgan failureUnivariate analysisCohort studyFrequent causeSevere entitySurvival rateP- 40 PENTOXIFYLLINE USE IN PATIENTS WITH ALCOHOL-ASSOCIATED HEPATITIS ADMITTED WITH ACUTE KIDNEY INJURY COULD DECREASE SURVIVAL: A GLOBAL STUDY
Idalsoaga F, Diaz L, Corsi O, Ayares G, Arnold J, Dunn W, Li Y, Singal A, Simonetto D, Ayala-Valverde M, Ramirez C, Morales-Arraez D, Zhang W, Qian S, Ahn J, Buryska S, Mehta H, Waleed M, Stefanescu H, Horhat A, Bumbu A, Agrawal B, Agrawal R, Cabezas J, Cuyàs B, Poca M, Pastor G, Sarin S, Maiwall R, Jalal P, La Tijera M, Kulkarni A, Rao N, Salazar P, Skladaný L, Bystrianska N, Prado V, Clemente-Sanchez A, Rincón D, Haider T, Chacko K, Romero G, Pollarsky F, Restrepo J, Toro L, Yaquich P, Mendizabal M, Garrido M, Marciano S, Dirchwolf M, Vargas V, Jimenez C, García-Tsao G, Ortiz G, Abraldes J, Kamath P, Shah V, Bataller R, Arab J. P- 40 PENTOXIFYLLINE USE IN PATIENTS WITH ALCOHOL-ASSOCIATED HEPATITIS ADMITTED WITH ACUTE KIDNEY INJURY COULD DECREASE SURVIVAL: A GLOBAL STUDY. Annals Of Hepatology 2024, 29: 101227. DOI: 10.1016/j.aohep.2023.101227.Peer-Reviewed Original ResearchAlcohol-associated hepatitisAcute kidney injurySevere AHPentoxifylline useLiver transplantationKidney injuryMaddrey's discriminant functionAssociated with increased mortalityHistory of cirrhosisSubgroup of patientsRetrospective cohort studyMultivariate-adjusted modelsEffect of pentoxifyllineAssociated with mortalityCompeting-risks modelMedian ageSerum creatinineMELD scoreUnivariate analysisCohort studyFemale sexPentoxifyllineDecreased survivalSevere entityPatientsCHAPTER 1 Introduction
Ortiz G, Garcia-Tsao G. CHAPTER 1 Introduction. 2024, 1-6. DOI: 10.1016/b978-0-323-87479-3.00010-7.ChaptersChronic liver diseasePortal hypertensionSustained liver injurySignificant portal hypertensionHealth care utilizationHepatic vein catheterizationStaging of fibrosisBurden of diseaseMost complicationsLiver injuryCare utilizationLiver diseaseVein catheterizationCirrhotic stageLiver stiffnessInvasive proceduresTime of interpretationDiffuse depositionSignificant causeAge groupsNoninvasive meansFibrous tissueSmall riskInterobserver variabilityGold standard
2023
Liver Transplantation for Mahvash Disease, an Inborn Error of Metabolism
Mistry P, Garcia-Tsao G. Liver Transplantation for Mahvash Disease, an Inborn Error of Metabolism. New England Journal Of Medicine 2023, 389: 2010-2013. PMID: 37991861, DOI: 10.1056/nejme2310332.Peer-Reviewed Original ResearchAGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review
Garcia-Tsao G, Abraldes J, Rich N, Wong V. AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review. Gastroenterology 2023, 166: 202-210. PMID: 37978969, DOI: 10.1053/j.gastro.2023.10.016.Peer-Reviewed Original ResearchConceptsSpontaneous bacterial peritonitisAcute kidney injuryLarge-volume paracentesisEffective arterial blood volumeVasoactive drugsVariceal hemorrhageArterial blood volumeHRS-AKIUncomplicated ascitesIntravenous albuminVolume statusPractice UpdateBlood volumeChronic liver failure grade 3Best practice advice statementsClinical Practice Updates CommitteeEnd-stage liver diseaseAGA Clinical Practice UpdateForms of AKIIntensive care unit monitoringAGA Governing BoardCombination of vasoconstrictorsInitial endoscopic hemostasisPatient's volume statusClinical Practice Update